Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization

Stefanie Derer, Christian Kellner, Thies Rösner, Katja Klausz, Pia Glorius, Thomas Valerius, Matthias Peipp

    1 Citation (Scopus)

    Abstract

    Therapeutic antibodies used in the treatment of cancer patients are able to mediate diverse effector mechanisms. Dependent on tumor entity, localization, and tumor burden different effector mechanisms may contribute to the in vivo antitumor activity to a variable degree. Especially Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) have been suggested as being important for the in vivo activity of therapeutic antibodies like rituximab or trastuzumab. In recent years, several strategies have been pursued to further optimize the cytotoxic potential of monoclonal antibodies by modifying their Fc part (Fc engineering) with the ultimate goal to enhance antibody therapy. Since Fc engineering approaches are applicable to any Fc-containing molecule, strategies to enhance CDC or ADCC activity of full antibodies or scFv-Fc fusion proteins by altering the primary Fc sequence are described.

    Original languageEnglish
    Title of host publicationMonoclonal Antibodies : Methods and Protocols
    Number of pages16
    PublisherHumana Press Inc.
    Publication date2014
    Pages525-540
    ISBN (Print)9781627039918
    DOIs
    Publication statusPublished - 2014

    Research Areas and Centers

    • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

    Fingerprint

    Dive into the research topics of 'Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization'. Together they form a unique fingerprint.

    Cite this